I - QUICK FACTS
· DID YOU KNOW...........for more than half a century it has been known that approximately 50% of CANCER DEATHS COULD HAVE BEEN PREVENTED with an effective early detection? (link)
· DID YOU KNOW...........there has been a BREAKTHROUGH INVENTION for early cancer detection? It is the only one demonstrating it goes “Beyond Imagination of Future Science”, accepted by one of the world's largest scientific conferences . The 3D-CBS is designed to be HUNDREDS OF TIMES MORE EFFICIENT than the current best cancer detection devices and is designed to use approximately 1/30th THE RADIATION, taking about 4 MINUTES TO EXAMINE THE ENTIRE BODY at a fraction of the current examination cost.
· DID YOU KNOW............. you can help play a part in improving cancer detection technology? Support this low cost, low radiation technology that is designed to be hundreds of times more efficient than current technology and for use on asymptomatic patients so that cancer can be detected at its onset when it is most curable.
WHAT IS THE 3D-CBS?
WHAT IS THE 3D-CBS?
The 3D-CBS is a patented technology designed to a use low level of radiation at a very low cost to drastically improve early cancer detection.
It is based on an invention designed to accurately capture as many signals as possible from radiation at the lowest cost per valid signal captured.
It uses technology designed to accurately detect small anomalies in biological processes in all organs of the human body, at a projected, low examination cost, long before anatomical changes occur. Unlike mammograms that screen only for breast cancer by detecting an anatomical anomaly, this new technology is designed to detect much smaller anomalies in biological processes through use of a low-radiation, complete body screening.
3-D Complete Body Screening
TARGETED TO EARLY CANCER DETECTION
Targeted to define prognosis of already formed tumors, mostly at an advanced stage
Information to physician
Designed to detect the slightest abnormal cancer metabolic activity (growth) at cellular level
Tumor dimensions of already-formed tumors when at a more advanced stage, or when already metastasized
Effectiveness for early cancer detection
Safe for screening
Radiation dose for screening should be less than 1mSv
use a low level of radiation (e.g. 0.5 mSv
Hazardous (e.g. 8-15 mSv using FDG)
Hazardous (e.g. 6-16 mSv using FDG)
Hazardous (e.g. 9-16 mSv using FDG)
Recognized to be THE FIRST TRUE TOTAL-BODY
Captures only tumor markers within its 16 cm FOV; unable to capture most oblique signals
Projected to be ~ $400
$1,500 to $4,000
(Scroll to bottom for notes from 2 to 17)
One person dies every 5 seconds from cancer somewhere in the world. It is indiscriminate when choosing its victims. It strikes the powerful and the famous, the rich and the poor, the young and the old.
We launch this project to raise funds to make the 3D-CBS breakthrough early cancer detection technology available with an invention by research scientist Dario Crosetto, described below.
Act now!Support this exceptional project that will revolutionize the medical field by changing the direction of the current approach to early cancer detection. By contributing to this project you can be part of this unique solution that is designed to detect cancer much earlier than existing technology.
What is lacking to solve the cancer problem?
One of the most serious problems facing medicine is late detection of cancer. Experimental data from several official sources agree that the earlier cancer is detected, the greater the survival rate (in most cases 90% to 98%). What is lacking is a screening method that is effective for early cancer detection. It needs to be rapid, sensitive, inexpensive, safe and effective in early detection of all types of cancer in all organs of the body. An effective screening method should use a device that is efficient in detecting, at a low cost, reliable signals showing the beginning of a mutation from normal cells into cancerous cells.
A breakthrough technology for solving the problem of cancer
Three-Dimensional Complete Body Screening (3D-CBS) technology makes it possible to build a medical imaging device that fits the above requirements. The 3D-CBS examination is designed to be:
· rapid (duration of the examination will be approximately 4 minutes),
· effective at detecting cancer and other diseases in all organs of the body at an early, curable stage;
· administering a safe dose of radiation, permitting annual usage,
· an improvement of the image quality,
· cost-effective to patients and their insurance company,
· changing the clinical character of Positron Emission Tomography (PET) into a preventive one, for use in early detection of cancer and other common diseases.
Dario Crosetto invented a technology that has been recognized by top scientists and experts from FERMIlab (U.S.), CERN, Geneva, Switzerland, Universities and industries in a formal, major, public scientific review held at FERMIlab that makes possible the discovery of new subatomic particles by thoroughly analyzing over 600 million events per second. This invention when applied to the field of medicine (when radiation is combined with tumor markers) offers a new weapon (the 3D-CBS) in the fight against cancer. Crosetto holds seven patents core to the 3D-CBS technology. The key parts of his inventions have been built in functional modular hardware that can easily migrate to future technologies.
What the inventor brings to the table to solve the cancer problem:
- His documentation for over 20 years,showing that he has been serving the scientific truth for the benefit of mankind.
- His commitment to continue to serve you in submitting pertinent and legitimate technical questions to decision makers that are in your best interest and work together to fulfill their responsibilities of the mandate that they received from you. (Read more...)
- The benefits from his inventions previously described in this document.
- The proof that he put you before any personal gain for himself. (Read more...)
- Eighty per cent from the income from licensing the patents of his invention to benefit humanity will be donated to fund programs that will reduce cancer deaths and costs and provide free 3D-CBS examinations for low-income patients.
BREAKTHROUGH INVENTION. The only one demonstrating going “Beyond Imagination of Future Science”, in the discovery of new subatomic particles and also in providing a significant leap forward in reducing premature cancer deaths and related costs through an effective early detection, accepted by one of the world's largest scientific IEEE conference
published several articles in scientific journals.
He published his basic invention in a 45 page article in one of the most prestigious peer-review scientific journal: Nuclear Instruments and Methods in Physics Research Sec. A, vol. 436 (1999) 341-385. It is rare for such journal to publish a 45 page article by a single author. This shows the merit of Crosetto’s work.
A synthesis of his innovations for medical imaging applications, when combining his basic invention with others he developed after the year 2000 can be found in the 2003 IEEE-NSS-MIC article: “The 3-D Complete Body Screening (3D-CBS). Features and Implementation” Conference record M7-129
Recognition of the invention
The 3D-CBS technology won the international Leonardo da Vinci Competition after five hours of public scrutiny (worldwide via internet) from the University of Pavia in Italy, comparing the 3D-CBS technology with projects from leading world research laboratories, cancer centers and individuals. It was also recognized valuable for early cancer detection by three international public (also webcasted) scientific reviews in 2003, 2008 and 2010.
A frequent comment from the public
Comment: “It is clear at this point that a greater survival rate can be obtained by detecting more accurately, more signals from the tumor markers, but why is it better than detecting another signal showing a change in odor, temperature, fluorescence, conductivity, or tissue density using X-ray, CT scan, MRI, Ultrasound, etc.?”
Response: “There are thousands of articles reporting that experimental results show that cancer cells grow faster than normal cells and because they grows faster, they require more nutrient, up to 70 times more than normal cells. Abnormal metabolism is an important signal related to the start of the mutation from normal cells into cancerous cells. Capturing more signals more accurately from tumor markers showing abnormal consumption of nutrient from body cells could provide advantages in early cancer detection. There are no similar advantages from other signals.”
Follow up comment: “I understand, and it makes sense! I want to have an exam like this. If a low cost screening of the entire body for all types of cancer in patients without symptoms but, at high risk, can be done effectively (capturing the majority of signals from any tumor markers combined with a radioisotope) with the 3D-CBS technology, requiring a low level of radiation dose, comparable to that of a mammogram then…
it would be a dramatic breakthrough in early cancer detection!
What you can Give: What you can Receive:
Don't let people continue to die needlessly without lifting a finger.
Edmund Burke stated:
“The only thing necessary for the triumph of evil is for good men to do nothing.”
“Nobody made a greater mistake than he who did nothing because he could do only little.”
II – ADVANTAGES OF 3D-CBS COMPARED TO CURRENT PET
The 3D-CBS technology: The 3D-CBS technology relies on the same nuclear reaction as current PET, however, it is unlike the 5,000 existing PET devices that do not capture most of the radiation. This is because they scan only a portion of the body and can only measure the dimensions of already-formed tumors. The 3D-CBS technology is designed for a cost-effective Complete Body Screening exam. It measures minimum abnormal consumption of nutrient by body cells or by detecting other anomalies, and is thus designed to achieve an effective early cancer detection. (Read more...)
Captures only 1 out of 10,000 photons Designed to capture 400 out of 10,000 photons
See animation at: http://links.unitedtoendcancer.info/doc2/PET_ani.swfFigure 1. Comparison between current PET and the 3D-CBS.
Figure 2. The 3D-CBS is designed to be more sensitive, require lower radiation, faster and to have a lower cost
(See Note 1 at the end of this document).
HOW WE CAN MAKE THIS WORK
Supporting this project would help all of us. Any contribution from $5 to whatever you can give will be useful to achieve the first goal of $100,000 to set up the infrastructure to develop this technology for an effective screening. It will make it possible to detect cancer at an early stage, thus improving the probability to prolong life.
This is the work plan:
- Raising $100,000 in two months through this crowd-funding effort to create the infrastructure to implement the following point: (Read more...)
- Laying down contracts and setting up an office in two months. (Read more...)
- Raising $20 million in six months from private investors to build the three 3D-CBS devices. (Read more...)
- Testing and regulatory approval
- Licensing the patents for the mass production of the 3D-CBS units. (Read more...)
- Implementing the Plan to mass produce the 3D-CBS device. (Read more...)
What you can do to help bring the benefits of this invention to you and to the public
- Please donate to save lives; every donation is valuable.
- Please help us share our campaign on Facebook and Twitter.
- Please tell all your friends.
- Please help us share the need for accountability in cancer research to get more results (Read more...)
- Please organize speaking opportunities. (Read more...)
- Please tell cancer organizations. (Read more...)
III – THE PERKS
Here is what you will receive for your donation
IV – THE TEAM
The plan is to create two positions after this first round of funding of $100,000 and eight additional positions after the contracts have been defined and the infrastructure to develop the 3D-CBS screening devices has been set up.
Dario Crosetto, Research Scientist
DeSoto, Texas, USA
The inventor, Dario Crosetto: Crosetto worked as a research scientist on physics experiments at CERN in Geneva, Switzerland, for 17 years before joining the Superconducting Super Collider (SSC) project in Texas in 1991 where he currently resides. He lectured at CERN School of Computing, and has published six books and 100+ articles. Crosetto received grants from the Department of Defense and the Department of Energy for approximately $1 million to pursue research in pattern recognition that breaks the speed barrier in real-time applications. In the course of his research, he realized that his technology could be utilized to detect a different type of matter: cancer cells. He then developed and patented the 3-D Complete Body screening technology as the first step toward creating early cancer-detection devices designed to be more effective than current technology.
He holds seven patents for the 3-D complete Body Screening technology. His goal is to make this technology a reality and seek to develop devices to help stop cancer through early detection. Crosetto has committed to donating the majority of the income from licensing his patents to provide free screening with an effective 3D-CBS device to low-income patients. (You can find additional information related to his invention: http://links.unitedtoendcancer.info/doc2/300.pdf, to the testimonials and evaluations from experts in the field who have appreciated Crosetto’s scientific approaches http://links.unitedtoendcancer.info/doc2/167.pdf and a selected bibliography of Crosetto’s articles related to this project http://links.unitedtoendcancer.info/doc2/168.pdf).
Plano, Texas, USA
Mr. Sonnino is the founder and CEO at RS INDUSTRIAL & MANAGEMENT CONSULTING, LLC, and is a 38 year veteran of the Semiconductor Industry, and is the former Group Vice President of ST Microelectronics (one of the world's largest Semiconductor Manufacturing Companies). He has held many Operational and Executive positions with activities in USA, Europe and Asia. Most significantly: 1. General Manager of the Analog & Logic Division; 2. Deputy General Manager for AMS Group (Analog , MEMS, Sensors)
Dr. Umberto Bellotti
Bene Vagienna, Italy
Dr. Bellotti is a physicist, researcher at the University of Pavia in solid state, plasma and e.m. branches until 1999, expert in computer and networking, renewable energies consultant.
Dr. Joseph Dent Ph.D.
Associate Professor Department of Biology
McGill University, N4/7 Stewart Biology Building
1205 Ave. Docteur Penfield
Montreal, QC, H3A 1B1
Dr. Dent is the Director of the lab that uses molecular, genetic and electrophysiological approaches in the model nematode Caenorhabitis elegans to examine the role of ligand-gated ion channel neurotransmitter receptors in the sensitivity of worms to antiparasitic drugs. The lab is also characterizing novel, invertebrate-specific receptors as potential targets for the development of new classes of antiparasitic compounds. Probing the structure of neurotransmitter receptors using fluorescent protein labelling and fluorescence resonance energy transfer to better understand how their protein subunit composition affects their pharmacology.
Eng. Vittorio Remondino Ph.D.
CERN (European Center for Particle Physics)
1211 Geneva 23
Eng. Remondino is on staff at CERN since 1980. He is a Specialist in Magnet Design, Measurements and Analysis of Accelerator for Particle Physics and is responsible for the measurement system of LHC dipole and quadrupole used at the factory premises. Follow-up of the quality during the production of the magnetic model of the LHC correction magnets. He is responsible for the post-processing of magnetic measurement data of the LHC lattice and spool-piece corrector magnets as well as magnets for the inner triplets. Dr. Remondino is also responsible for the creation of a unified database of quench performance of all LHC magnets during tests.
DeSoto, Texas USA
Ms. D'Amari's professional and personal edict: "Success is achieved through dedication and the understanding of the needs and desires of others". She is the author of a successful structure and system to guide the public through the title process in the title insurance industry. Coming to Texas from Ohio, Ms. D'Amari is dedicated to promote the implementation of the 3D-CBS and looks forward to its success.
Note1 - No initial prototype has been built for this device. The crowd-funding effort seeks to begin the process of creating the necessary working prototypes. FDA approval will be necessary to utilize this device to detect cancer. FDA approval can only be sought after construction and testing of the prototypes. The projections regarding lives that could be saved are based upon the study, results from simulation of different parts of the system, predictive modeling and the scientific and technological assumptions which lead to the above estimated figures. The next step is to build three prototypes to confirm this study and these estimates with measurements as described at this link. Nothing in this Indiegogo crowd-funding project seeks to solicit investor funds and this Indiegogo project is not promising such funds will be raised. This project seeks only to raise $100,000 based upon provisions of the perks set forth herein.
Note2 - The $850 annual average cancer cost per person for people in an industrialized country has been calculated by dividing the United States cancer cost in 2010 of $263.8 billion (http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf) by its population of 308 million.
LIST OF ALL NOTES INCLUDING THOSE FROM THE TABLE:
 Link to the 2013 IEEE-NSS-MIC-RTSD conference in Seoul, Korea on October 27, November 3, 2013 http://links.unitedtoendcancer.info/doc2/366.pdf
 Website comparing PET/CT from GE, Siemens and Philips http://www.itnonline.com/comparison-charts?t=PET+%26%2347%3B+CT+Systems
 Articles describing the 3D-CBS innovative technology presented by Crosetto at the IEEE-NSS-MIC conferences in 2000 and 2003. See: http://links.unitedtoendcancer.info/doc2/69.pdf and http://links.unitedtoendcancer.info/doc2/107.pdf. Crosetto’s effort to increase PET efficiency has been translated in a study based on his innovative 3D-CBS technology (see http://links.unitedtoendcancer.info/doc2/431.pdf). He presented a plan (see www.u2ec.org) to build three prototypes to be tested on a sample population aged 50-75 in a location with a constant death rate over the past 20 years. The advantages of his innovative 3D-CBS technology, his plan to build three prototypes and test them on a sample population, providing the benefits of reducing cancer deaths and cost have been discussed in several public forums. No one has been able to invalidate with scientific arguments Crosetto’s claim that his invention would greatly reduce premature cancer deaths and cost. Therefore, funding should be provided to implement 3D-CBS prototypes instead of funding less efficient projects that did not go through this public scientific procedure. A difference or no difference in the mortality rate will quantify the success or failure of his proposed solution.
 Philips Gemini LXL, PET/CT http://www.medwow.com/med/pet-ct/philips/gemini-lxl/55453.model-spec
 Siemens Biograph TruePoint, PET/CT http://www.activexray.com/pdf/Siemens_Biograph.pdf
 GE Discovery 710, PET/CT http://www3.gehealthcare.com/en/Products/Categories/PET-CT/PET-CT_Scanners/Discovery_PET-CT_710
 The innovations of the 3D-CBS technology will make it possible to achieve an effective EARLY CANCER DETECTION, and also improve the prognosis for the majority of tumors.
 A physician could receive precious information from instrumentations and make a correct diagnosis to avoid false positives and false negatives when the technique behind each instrument is understood and developed to its full potential. Positron Emission Technique works best when providing information of the slightest abnormal metabolic activity (consumption of nutrient, growth, and for showing other abnormal biological processes tagged by a radionuclide) that other techniques such as Computed Tomography (CT), Ultrasound, Magnetic Resonance Imaging (MRI), X-ray, etc., cannot provide. This is what a physician should expect, request and focus on a PET technique: an instrument that precisely measures the slightest abnormal metabolism. It would be an inappropriate use of PET to measure dimensions and CT to measure activities of biological processes at the molecular level, as by analogy it would be inappropriate to use a water meter to measure dimensions and a ruler to measure monthly water consumption. The 3D-CBS develops this technique to its potential in a cost-effective instrument that provides the maximum efficiency in accurately detecting all possible signals from the tumor markers at the lowest cost per valid signal captured.
 It is improper for physicians, oncologists, hospital administrators, etc., to ask PET manufacturers: “What is the spatial resolution of your PET?” instead of asking: “What is the accuracy of your PET in detecting the slightest abnormality in a specific biological process tagged with a radionuclide?” They do not ask what the spatial resolution is of a heart monitor rate device or of an electric kWh meter, because they relate the technique used by the instrument to perform the measurement with the information they expect from the instrument. Therefore, it is inappropriate to ask PET manufacturers to increase the spatial resolution of a device whose technique features an inherent error that can be of several mm due to two natural phenomena that cannot be eliminated. Actually, the tumor can be at a distance of several millimeters from where it appears to be from the image, and could show a significant dimensional error. This is because each positron, originating in the tumor, travels before encountering an electron and then annihilates generating two photons that will be detected by the PET. The distance travelled is called “positron range” and depends on the radionuclide used (it is 13.8 mm for Rubidium; 82, 4.5 mm for Oxygen-15, etc.). The second source of error is the “collinearity error”: the photons generated do not diverge at exactly 180°; the difference in their angle when projected on the crystal detectors generates an extra error of up to ~ 1.5 mm. Physicians, oncologists and hospital administrators, instead of insisting with PET manufacturers to increase spatial resolution, they should ask for an improvement in the accuracy of measuring the slightest abnormal biological process activity. This would provide important information that they were not aware was possible (beyond their imagination) that would contribute to a more accurate diagnosis. It is important for physicians, oncologists and hospital administrators to better understand the physics on which the instrument rely. By doing so they can ask for useful information that the instrument can provide and not ask for an improvement in the measurement of parameters within the limitations of the technique used by the instrument that will not be helpful in making a more precise diagnosis aimed at saving a patient’s life.
 The 3D-CBS is designed to be effective for early cancer detection because it is efficient, safe and has a low examination cost. These features are achieved because the 3D-CBS is designed to accurately capture all possible signals from the tumor markers at the lowest cost per valid signal captured. High efficiency allows: (a) the detection of minimum abnormal metabolism which is a reason to suspect cancer cells as they consume up to 70 times more nutrient than normal cells (b) requires a safe, low radiation dose (0.5% mSv, 1/30 of the dose required by current PET and 50% less than 1 mSv which is the maximum dose for screening recommended by the International Commission for Radiation Protection –ICRP-) and (c) a low examination cost because of the higher patient throughput given the fact that the 3D-CBS can collect more valid data in a shorter time.
 Efficiency is defined as the number of 511 keV pairs of photons detected by the device divided by the number of 511 keV pairs of photons generated by the annihilation of a positron with an electron.
The efficiency of the 3D-CBS is “Very High” because the Field Of View (FOV) of the 3D-CBS is much longer (140 cm vs. 16-18 cm of current PET), therefore the 3D-CBS will capture significantly more pairs of photons because their number is approximately proportional to the square of the increase in length of the detector. In addition, the efficiency of the 3D-CBS is also increased (a) by the 3D-Flow parallel-processing system capable of accurately capturing as many signals as possible from the tumor markers, (b) by the simplified, detector assembly and (c) by its capability to execute 3 x 3, or 4 x 4 real-time complex algorithms for a duration longer than the time interval between two consecutive input data.
 Current PET are not suitable for early cancer detection because of their low efficiency, high radiation requirement that makes it hazardous for screening, and a high examination cost. Capturing insufficient signals from the tumor markers does not allow for early detection. Current PET can see an anomaly in cell metabolism only when the tumor is large or very active at an advance stage. Tumors detected at an advanced stage have a much lower probability to be cured and save patient’s life. Current PET devices require over 10 times the maximum radiation dose recommended by ICRP, thus not permitted for screening. The examination cost is high because patients’ throughput is low due to the fact that a longer time is needed to acquire sufficient data for reliable statistics that would avoid “false positives” and “false negatives”.
 The efficiency of the existing PET devices (GE, Philips and Siemens) is “Very Low” because the Field Of View (FOV) is only 16 to 18 cm. This statement is very simple to be verified in any hospital or clinic that utilizes a PET. You may ask the PET operator how many valid pairs of 511 keV signals from tumor markers its PET is able to record per second during a specific examination. The total number of pairs of 511keV tumor marker signals generated per second depends on the dose of radionuclide administered to the patient; 10 mCi of radionuclide (the average amount of radionuclide per examination used for current PET) generates 370 million pairs per second. The EFFICIENCY for any specific PET device can be calculated by dividing the number of valid 511 keV pairs of signals captured by the total number of pairs generated by the radionuclide.
 The meaning of TRUE TOTAL-BODY is a device that can perform a single examination for most organs, capturing tumor markers from the entire body at one time in a stationary position.
 G. Borasi, F. Fioroni, A. Del Guerra and G. Lucignani. European Journal of Nuclear Medicine and Molecular Imaging (2010) 37:1629–1632. Article from leaders in the field stating that Crosetto’s 3D-CBS technology is the first, true “total-body” PET system.
 Current PET although they might be called Whole-Body PET are not TRUE TOTAL BODY because their detector length is only approximately 16 cm to 18 cm. They are unable to detect most of the oblique signals generated from the tumor markers. This limitation does not allow all three advantages that make early cancer detection effective: (a) high efficiency, (b) a low, safe radiation dose and (c) a low examination cost.
 The examination duration must allow for the capture of enough data to form reliable statistics for different parts of the body showing the slightest abnormal metabolism. The 3D-CBS can capture hundreds of times more data per second compared to current PET. This is because the 3D-CBS captures signals from tumor markers all at once from the entire body lying in a stationary position with a detector that is 140 cm long. The current PET is missing signals from the tumor markers arriving at an angle because the detector is only 16 cm in length. This requires positioning the detector on eleven different parts of the body. The specifications of GE Discovery PET/CT 710 states that the duration of the examination should be the “physician’s preference”. His preference should allow enough data to be acquired and therefore avoid “false positives” and “false negatives.” In order to obtain comparable statistical data, the duration of the examination on current PET should be hundreds of times longer than the 3D-CBS examination, which captures hundreds of times more signals per second. This would be impractical, not only for the difficulty and discomfort to remain still for several hours, but also because the radionuclide would cease activity. It is reasonable to expect the examination time for the current PET to last at least ten times longer than the 3D-CBS (40 minutes vs. 4 minutes) in order to provide reliable information to reject at least “false positives” and “false negatives”. However, unlike the 3D-CBS, the acquired data by the current PET would still not provide enough information to make early cancer detection possible. The values in this table do not match those indicated by the manufacturers, however, it would be appropriate for each physician to adopt the suggested 40 minute examination time for GE Discovery PET/CT 710 and Siemens Biograph TruePoint having a detector length of ~ 16 cm, and 35 minutes for Philips Gemini LXL that has a detector length of 18 cm
 Patents: US 7,584,446 B2; US 7,262,415 B2US 7,217,928 B2; US 7,180,074 B1; US 7,132,664 B1; US 7,051,309 B1; US 5,937,202. Nothing in this Indiegogo crowd-funding project seeks to solicit investor funds and is not promising such funds will be raised. This project seeks only to raise $100,000 on provisions of the perks set forth herein